1309430-81-6

Basic information

• Product Name: 7H-Pyrrolo[2,3-d]pyrimidine, 4-(1-methylethyl)-
• CAS NO: 1309430-81-6
• Molecular Formula: C9H11N3
• Molecular Weight: 161.20400
• Mol File: 1309430-81-6.mol

Chemical Properties

• Density: 1.164±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 7H-Pyrrolo[2,3-d]pyrimidine, 4-(1-methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 7H-Pyrrolo[2,3-d]pyrimidine, 4-(1-methylethyl)-(1309430-81-6)
• EPA Substance Registry System: 7H-Pyrrolo[2,3-d]pyrimidine, 4-(1-methylethyl)-(1309430-81-6)

Safety Data

• Hazardous Substances Data: 1309430-81-6(Hazardous Substances Data)

Upstream product

• 920-39-8 isopropylmagnesium bromide 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 271-70-5 7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

Condensed Fukui function predicts innate C-H radical functionalization sites on multi-nitrogen containing fused arenes

The condensed Fukui function could be correlated with the reported innate C-H radical functionalization sites on some heterocycles. This computational method was further extended to predict the innate C-H functionalization sites on multi-nitrogen containi

NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS

The present invention relates to the synthesis of 6-substituted 7-deazapurines and their corresponding nucleosides by coupling aryl or alkyl Grignard reagents with halogenated purine nucleosides in the presence of iron or an iron/copper mixture such as Fe(acac)3/Cul. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.

Iron/Copper Co-Catalyzed Cross-Coupling Reaction for the Synthesis of 6-Substituted 7-Deazapurines and the Corresponding Nucleosides

An efficient access to 6-substituted 7-deazapurine and the corresponding nucleosides by coupling aryl or alkyl Grignard reagents and halogenated purine nucleosides in the presence of Fe(acac)3/CuI is described. A series of 6-substituted 7-deazapurines and the corresponding nucleosides were obtained in medium to good yields. For the synthesis of modified nucleosides that will be the subject of biological testing, we propose to use iron-catalyzed instead of palladium-catalyzed reaction. The synthesized compounds were tested for their antiproliferative activity. The cytotoxicity study of compounds 11a-q shows that by modifying the 6-position of 7-deazapurine ribonucleosides, the compounds may become selective for certain cancer cell lines.

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.